DOCSLIB.ORG

Genepanel Mitochondrial Diseases Genepanel Paediatric Cardiomyopathy AARS2 AARS2 ABAT ABCC6 ACAD9 ABCC9 ACO2 ACAD8 AFG3L2 ACAD9

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genepanel Mitochondrial Diseases Genepanel Paediatric Cardiomyopathy AARS2 AARS2 ABAT ABCC6 ACAD9 ABCC9 ACO2 ACAD8 AFG3L2 ACAD9 Supplementary material J Med Genet Genepanel mitochondrial diseases Genepanel paediatric cardiomyopathy AARS2 AARS2 ABAT ABCC6 ACAD9 ABCC9 ACO2 ACAD8 AFG3L2 ACAD9 AGK ACADS AIFM1 ACADVL ALDH1B1 ACTA1 ANO10 ACTC1 APOPT1 ACTN2 APTX ADCY5 ATAD3A AGK ATAD3B AGL ATP13A2 AGPAT2 ATP5F1A AHCY ATP5F1B AIP ATP5F1C ALG1 ATP5F1D ALG6 ATP5F1E ALMS1 ATP5IF1 ALPK3 ATP5MC1 ANKRD1 ATP5MC2 ANKRD11 ATP5MC3 ANKS6 ATP5ME ANO5 ATP5MF APOPT1 ATP5MG ARSB ATP5MGL ASNA1 ATP5PB ATP5E ATP5PD ATP6V1B2 ATP5PF ATPAF2 ATP5PO BAG3 ATP5S BBS2 ATPAF1 BCS1L ATPAF2 BOLA3 BCS1L BRAF BOLA1 BRCA2 BOLA2 BRCC3 BOLA3 BRIP1 C12orf65 BSCL2 C19orf12 C10ORF2 C19orf70 CALR3 C1QBP CASQ1 CA5A CAV1 CARS2 CAV3 CEP89 CDKN1C CHCHD10 CHKB CHKB CHRM2 CLPB CISD2 CLPP COA5 Almomani R, et al. J Med Genet 2019; 0:1–8. doi: 10.1136/jmedgenet-2019-106330 Supplementary material J Med Genet COA1 COA6 COA3 COG7 COA5 COL7A1 COA6 COQ2 COA7 COQ4 COASY COX10 COQ2 COX14 COQ4 COX20 COQ5 COX6B1 COQ6 COX7B COQ7 CPT1A COQ8A CPT2 COQ8B CRYAB COQ9 CSRP3 COX10 CTNNA3 COX14 D2HGDH COX15 DCAF8 COX20 DCHS1 COX4I1 DES COX4I2 DLD COX5A DMD COX5B DMPK COX6A1 DNAJC19 COX6A2 DOLK COX6B1 DPM3 COX6B2 DSC2 COX6C DSG2 COX7A1 DSP COX7A2 DTNA COX7B DYSF COX7B2 ELAC2 COX7C EMD COX8A ENPP1 COX8C EPG5 CP ERBB3 CTBP1 ERCC4 CYC1 EYA4 CYCS FAH DARS2 FANCA DCAF17 FANCB DDHD1 FANCC DES FANCD2 DGUOK FANCE DHTKD1 FANCF DLAT FANCG DLD FANCI DLST FANCL DMAC1 FANCM DMAC2 FASTKD2 DNA2 FBN1 Almomani R, et al. J Med Genet 2019; 0:1–8. doi: 10.1136/jmedgenet-2019-106330 Supplementary material J Med Genet DNAJC19 FBXL4 DNAJC3 FHL1 DNM1L FHL2 EARS2 FIG4 ECHS1 FKRP ECSIT FKTN EHHADH FLNA ELAC2 FLNC ERAL1 FOS ETHE1 FOXD4 FA2H FOXRED1 FARS2 FTO FASTKD2 FXN FBXL4 GAA FDX2 GATA4 FDXR GATAD1 FH GATB FOXRED1 GATC FTL GBE1 FXN GJA5 GARS GLA GATB GLB1 GATC GMPPB GATM GNAS GFER GNPTAB GFM1 GNS GFM2 GPC3 GLRX5 GPR101 GLUD1 GSN GTPBP2 GTPBP3 GTPBP3 GYS1 HARS2 HADH HCCS HADHA HIBCH HADHB HLCS HAMP HSD17B10 HBB HSPA9 HCCS HSPD1 HCN4 HTRA2 HFE IARS2 HFE2 IBA57 HGSNAT ISCA2 HPS1 ISCU HRAS KARS HSD17B10 LACTB HSPB6 LARS2 IDH2 LIAS IDUA LIPT1 IGF2 LIPT2 ILK LONP1 ISL1 Almomani R, et al. J Med Genet 2019; 0:1–8. doi: 10.1136/jmedgenet-2019-106330 Supplementary material J Med Genet LRPPRC ITGB1BP2 LYRM4 JPH2 LYRM7 JUP MARS2 KCNH1 MCUR1 KCNH2 MDH2 KIF20A MECR KLF1 MFF KRAS MFN2 LAMA4 MGME1 LAMP2 MICU1 LDB3 MICU2 LIAS MIEF2 LMNA MIPEP MAP2K1 MPC1 MAP2K2 MPV17 MGME1 MRM2 MIB1 MRPL12 MLYCD MRPL3 MRPL3 MRPL40 MRPL44 MRPL44 MRPS22 MRPL57 MTCP1 MRPS16 MTO1 MRPS2 MURC MRPS22 MUT MRPS23 MYBPC3 MRPS34 MYH6 MRPS7 MYH7 MRRF MYL2 MSTO1 MYL3 MTFMT MYLK2 MTO1 MYOT MTPAP MYOZ1 NARS2 MYOZ2 NAXE MYPN NDUFA1 NAGA NDUFA10 NAGLU NDUFA11 NDUFA1 NDUFA12 NDUFA11 NDUFA13 NDUFAF1 NDUFA2 NDUFAF2 NDUFA3 NDUFAF3 NDUFA4 NDUFAF4 NDUFA5 NDUFAF5 NDUFA6 NDUFB11 NDUFA7 NDUFB3 NDUFA8 NDUFB9 NDUFA9 NDUFS1 NDUFAB1 NDUFS2 NDUFAF1 NDUFS3 Almomani R, et al. J Med Genet 2019; 0:1–8. doi: 10.1136/jmedgenet-2019-106330 Supplementary material J Med Genet NDUFAF2 NDUFS4 NDUFAF3 NDUFS6 NDUFAF4 NDUFV1 NDUFAF5 NDUFV2 NDUFAF6 NEBL NDUFAF7 NEU1 NDUFB1 NEXN NDUFB10 NF1 NDUFB11 NKX2-5 NDUFB2 NPPA NDUFB3 NRAS NDUFB4 NSD1 NDUFB5 NUBPL NDUFB6 PALB2 NDUFB7 PCCA NDUFB8 PCCB NDUFB9 PDGFRA NDUFC1 PDLIM3 NDUFC2 PET100 NDUFS1 PEX1 NDUFS2 PEX10 NDUFS3 PEX11B NDUFS4 PEX12 NDUFS5 PEX13 NDUFS6 PEX14 NDUFS7 PEX16 NDUFS8 PEX19 NDUFV1 PEX2 NDUFV2 PEX26 NDUFV3 PEX3 NFS1 PEX5 NFU1 PEX6 NSUN3 PEX7 NUBPL PGM1 OGDH PHYH OPA1 PIGT OPA3 PKP2 OXA1L PLEC PANK2 PLEKHM2 PARS2 PLN PC PMM2 PDHA1 PNPLA2 PDHB POLG PDHX POMT1 PDK1 POU1F1 PDK2 PPARG PDK3 PRDM16 PDK4 PRKAG2 PDP1 PRPS1 PDSS1 PSEN1 Almomani R, et al. J Med Genet 2019; 0:1–8. doi: 10.1136/jmedgenet-2019-106330 Supplementary material J Med Genet PDSS2 PSEN2 PET100 PTPN11 PET117 QRSL1 PIGA RAB3GAP2 PITRM1 RAD51C PMPCA RAF1 PMPCB RBCK1 PNPT1 RBM20 POLG RET POLG2 RIT1 PPA2 RMND1 PRKAA1 RYR2 PTRH2 SCARB2 PUS1 SCN5A PYCR1 SCO1 PYCR2 SCO2 QRSL1 SDHA RARS2 SDHAF1 RMND1 SDHD RNASEH1 SEPN1 RRM2B SGCA RTN4IP1 SGCB SACS SGCD SAMHD1 SGSH SARS2 SHOC2 SCO1 SKI SCO2 SLC19A2 SCP2 SLC22A5 SDHA SLC25A20 SDHAF1 SLC25A3 SDHB SLC25A4 SDHD SLC2A10 SERAC1 SLX4 SFXN4 SNAP29 SLC19A2 SOD2 SLC19A3 SOS1 SLC25A1 SPEG SLC25A10 SYNE1 SLC25A12 SYNE2 SLC25A13 TACO1 SLC25A19 TAZ SLC25A21 TBX20 SLC25A22 TCAP SLC25A24 TERT SLC25A3 TGFB1 SLC25A32 TGFB3 SLC25A4 TMEM126A SLC25A42 TMEM43 SLC25A46 TMEM70 SLC39A8 TMPO Almomani R, et al. J Med Genet 2019; 0:1–8. doi: 10.1136/jmedgenet-2019-106330 Supplementary material J Med Genet SLC52A2 TNNC1 SLC52A3 TNNI3 SPART TNNI3K SPATA5 TNNT2 SPG7 TPI1 SQSTM1 TPM1 STAT2 TPM3 STXBP1 TRNT1 SUCLA2 TSFM SUCLG1 TTN SUCLG2 TTPA SURF1 TTR TACO1 TXNRD2 TANGO2 UBE2T TARS2 UBR1 TAZ VCL THG1L VPS13A TIMM44 WFS1 TIMM50 XK TIMM8A XPNPEP3 TIMMDC1 YARS2 TK2 TMEM126A TMEM126B TMEM186 TMEM65 TMEM70 TPK1 TRIT1 TRMT10C TRMT5 TRMU TRNT1 TSFM TTC19 TUFM TWNK TXN2 TYMP UQCC1 UQCC2 UQCC3 UQCR10 UQCR11 UQCRB UQCRC1 UQCRC2 UQCRFS1 UQCRH UQCRQ Almomani R, et al. J Med Genet 2019; 0:1–8. doi: 10.1136/jmedgenet-2019-106330 Supplementary material J Med Genet VARS2 VPS13D WARS2 WDR45 YARS2 YME1L1 Supplemental Table 1. Likely pathogenic or pathogenic variants in these genes were excluded in patient X:1. Of note, there is some overlap between both panels. Almomani R, et al. J Med Genet 2019; 0:1–8. doi: 10.1136/jmedgenet-2019-106330 Supplementary material J Med Genet Almomani R, et al. J Med Genet 2019; 0:1–8. doi: 10.1136/jmedgenet-2019-106330 Supplementary material J Med Genet Almomani R, et al. J Med Genet 2019; 0:1–8. doi: 10.1136/jmedgenet-2019-106330 Supplementary material J Med Genet Almomani R, et al. J Med Genet 2019; 0:1–8. doi: 10.1136/jmedgenet-2019-106330 Supplementary material J Med Genet Almomani R, et al. J Med Genet 2019; 0:1–8. doi: 10.1136/jmedgenet-2019-106330 Supplementary material J Med Genet Almomani R, et al. J Med Genet 2019; 0:1–8. doi: 10.1136/jmedgenet-2019-106330 Supplementary material J Med Genet Almomani R, et al. J Med Genet 2019; 0:1–8. doi: 10.1136/jmedgenet-2019-106330 Supplementary material J Med Genet Almomani R, et al. J Med Genet 2019; 0:1–8. doi: 10.1136/jmedgenet-2019-106330 Supplementary material J Med Genet X:1. Almomani R, et al. J Med Genet 2019; 0:1–8. doi: 10.1136/jmedgenet-2019-106330.
Load more

Recommended publications
  • NDUFAF1 Antibody
    Efficient Professional Protein and Antibody Platforms NDUFAF1 Antibody Basic information: Catalog No.: UPA63763 Source: Rabbit Size: 50ul/100ul Clonality: monoclonal Concentration: 1mg/ml Isotype: Rabbit IgG Purification: Protein A purified. Useful Information: WB:1:1000 ICC:1:50-1:200 Applications: IHC:1:50-1:200 FC:1:50-1:100 Reactivity: Human Specificity: This antibody recognizes NDUFAF1 protein. Immunogen: Synthetic peptide within C terminal human NDUFAF1. This gene encodes a complex I assembly factor protein. Complex I (NADH-ubiquinone oxidoreductase) catalyzes the transfer of electrons from NADH to ubiquinone (coenzyme Q) in the first step of the mitochondrial respiratory chain, resulting in the translocation of protons across the inner mitochondrial membrane. The encoded protein is required for assembly of complex I, and mutations in this gene are a cause of mitochondrial complex I deficiency. Alternatively spliced transcript variants have been observed for Description: this gene, and a pseudogene of this gene is located on the long arm of chromosome 19. Part of the mitochondrial complex I assembly (MCIA) com- plex. The complex comprises at least TMEM126B, NDUFAF1, ECSIT, and ACAD9. Interacts with ECSIT. Interacts with ACAD9. At early stages of com- plex I assembly, it is found in intermediate subcomplexes that contain dif- ferent subunits including NDUFB6, NDUFA6, NDUFA9, NDUFS3, NDUFS7, ND1, ND2 and ND3 Uniprot: Q9Y375 Human BiowMW: 38 kDa Buffer: 1*TBS (pH7.4), 1%BSA, 50%Glycerol. Preservative: 0.05% Sodium Azide. Storage: Store at 4°C short term and -20°C long term. Avoid freeze-thaw cycles. Note: For research use only, not for use in diagnostic procedure.
    [Show full text]
  • Molecular Mechanism of ACAD9 in Mitochondrial Respiratory Complex 1 Assembly
    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.07.425795; this version posted January 9, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Molecular mechanism of ACAD9 in mitochondrial respiratory complex 1 assembly Chuanwu Xia1, Baoying Lou1, Zhuji Fu1, Al-Walid Mohsen2, Jerry Vockley2, and Jung-Ja P. Kim1 1Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, USA 2Department of Pediatrics, University of Pittsburgh School of Medicine, University of Pittsburgh, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA 15224, USA Abstract ACAD9 belongs to the acyl-CoA dehydrogenase family, which catalyzes the α-β dehydrogenation of fatty acyl-CoA thioesters. Thus, it is involved in fatty acid β-oxidation (FAO). However, it is now known that the primary function of ACAD9 is as an essential chaperone for mitochondrial respiratory complex 1 assembly. ACAD9 interacts with ECSIT and NDUFAF1, forming the mitochondrial complex 1 assembly (MCIA) complex. Although the role of MCIA in the complex 1 assembly pathway is well studied, little is known about the molecular mechanism of the interactions among these three assembly factors. Our current studies reveal that when ECSIT interacts with ACAD9, the flavoenzyme loses the FAD cofactor and consequently loses its FAO activity, demonstrating that the two roles of ACAD9 are not compatible. ACAD9 binds to the carboxy-terminal half (C-ECSIT), and NDUFAF1 binds to the amino-terminal half of ECSIT. Although the binary complex of ACAD9 with ECSIT or with C-ECSIT is unstable and aggregates easily, the ternary complex of ACAD9-ECSIT-NDUFAF1 (i.e., the MCIA complex) is soluble and extremely stable.
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • High-Throughput, Pooled Sequencing Identifies Mutations in NUBPL And
    ARTICLES High-throughput, pooled sequencing identifies mutations in NUBPL and FOXRED1 in human complex I deficiency Sarah E Calvo1–3,10, Elena J Tucker4,5,10, Alison G Compton4,10, Denise M Kirby4, Gabriel Crawford3, Noel P Burtt3, Manuel Rivas1,3, Candace Guiducci3, Damien L Bruno4, Olga A Goldberger1,2, Michelle C Redman3, Esko Wiltshire6,7, Callum J Wilson8, David Altshuler1,3,9, Stacey B Gabriel3, Mark J Daly1,3, David R Thorburn4,5 & Vamsi K Mootha1–3 Discovering the molecular basis of mitochondrial respiratory chain disease is challenging given the large number of both mitochondrial and nuclear genes that are involved. We report a strategy of focused candidate gene prediction, high-throughput sequencing and experimental validation to uncover the molecular basis of mitochondrial complex I disorders. We created seven pools of DNA from a cohort of 103 cases and 42 healthy controls and then performed deep sequencing of 103 candidate genes to identify 151 rare variants that were predicted to affect protein function. We established genetic diagnoses in 13 of 60 previously unsolved cases using confirmatory experiments, including cDNA complementation to show that mutations in NUBPL and FOXRED1 can cause complex I deficiency. Our study illustrates how large-scale sequencing, coupled with functional prediction and experimental validation, can be used to identify causal mutations in individual cases. Complex I of the mitochondrial respiratory chain is a large ~1-MDa ­assembly factors are probably required, as suggested by the 20 factors macromolecular machine composed of 45 protein subunits encoded necessary for assembly of the smaller complex IV9 and by cohort by both the nuclear and mitochondrial (mtDNA) genomes.
    [Show full text]
  • Mechanistic Studies on Medium Chain Acyl-Coa Dehydrogenase
    Acyl-CoA Dehydrogenases: Mechanistic studies on Medium Chain Acyl-CoA Dehydrogenase Dissertation zur Erlangung des akademischen Grades des Doktors der Naturwissenschaften (Dr. rer. nat.) an der Universität Konstanz (Fachbereich Biologie) vorgelegt von Vasile Robert Gradinaru Konstanz, im Juni 2005 Tag der mündlichen Prüfung : 9. November 2005 Referent: Prof. Dr. Sandro Ghisla Referent: Prof. Dr. Peter Macheroux Acknowledgements I am greatly indebted to my supervisor, Prof. Dr. Sandro Ghisla, for his advice and support. He has been an excellent supervisor providing insightful comments and constructive criticism throughout this PhD project. I would also like to thank my colleagues in the Universities of Konstanz and Iasi for their advice, encouragement and friendship, without which I would certainly not have completed this thesis. In particular, I would like to thank Prof. Dr. Richard Schowen, Prof. Dr. Peter Macheroux, Prof. Dr. Colin Thorpe, Prof. Dr. Jung-Ja. Kim, Prof. Dr. Tatiana Nicolaescu, Prof. Dr. Constantin Ciugureanu, Prof. Dr. Robert Bach, Dr. Olga Dmitrenko, Susanne Feindler-Boeckh, Gudrun Vogt, Elmi Leisner, Karl Janko, Lili Smau, Nasser Ibrahim, Phaneeswara Rao Kommoju, Sudarshan Rao Ande, Lakshminarayana Kaza, Cosmin Pocanschi, Paula Bulieris for their active interest during the course of this project. My gratitude also goes to Prof. Alexandru Cecal for encouraging me to embark on this PhD. I express my loving thanks to my wife Luiza whose love, support, patience and understanding made this work easier. Above all, I wish to express my sincerest gratitude to my parents, who made my studies possible and who have always encouraged me. This study was financiarlly supported by the Deutsche Forschungsgemeinschaft (Gh 2/6-4).
    [Show full text]
  • Location Analysis of Estrogen Receptor Target Promoters Reveals That
    Location analysis of estrogen receptor ␣ target promoters reveals that FOXA1 defines a domain of the estrogen response Jose´ e Laganie` re*†, Genevie` ve Deblois*, Ce´ line Lefebvre*, Alain R. Bataille‡, Franc¸ois Robert‡, and Vincent Gigue` re*†§ *Molecular Oncology Group, Departments of Medicine and Oncology, McGill University Health Centre, Montreal, QC, Canada H3A 1A1; †Department of Biochemistry, McGill University, Montreal, QC, Canada H3G 1Y6; and ‡Laboratory of Chromatin and Genomic Expression, Institut de Recherches Cliniques de Montre´al, Montreal, QC, Canada H2W 1R7 Communicated by Ronald M. Evans, The Salk Institute for Biological Studies, La Jolla, CA, July 1, 2005 (received for review June 3, 2005) Nuclear receptors can activate diverse biological pathways within general absence of large scale functional data linking these putative a target cell in response to their cognate ligands, but how this binding sites with gene expression in specific cell types. compartmentalization is achieved at the level of gene regulation is Recently, chromatin immunoprecipitation (ChIP) has been used poorly understood. We used a genome-wide analysis of promoter in combination with promoter or genomic DNA microarrays to occupancy by the estrogen receptor ␣ (ER␣) in MCF-7 cells to identify loci recognized by transcription factors in a genome-wide investigate the molecular mechanisms underlying the action of manner in mammalian cells (20–24). This technology, termed 17␤-estradiol (E2) in controlling the growth of breast cancer cells. ChIP-on-chip or location analysis, can therefore be used to deter- We identified 153 promoters bound by ER␣ in the presence of E2. mine the global gene expression program that characterize the Motif-finding algorithms demonstrated that the estrogen re- action of a nuclear receptor in response to its natural ligand.
    [Show full text]
  • A Genetic Dissection of Mitochondrial Respiratory Chain Biogenesis
    A GENETIC DISSECTION OF MITOCHONDRIAL RESPIRATORY CHAIN BIOGENESIS An Undergraduate Research Scholars Thesis by AARON GRIFFIN, SARAH THERIAULT, SHRISHIV TIMBALIA Submitted to Honors and Undergraduate Research Texas A&M University in partial fulfillment of the requirements for the designation as an UNDERGRADUATE RESEARCH SCHOLAR Approved by Research Advisor: Dr. Vishal Gohil May 2014 Major: Biochemistry, Genetics Biochemistry Biochemistry TABLE OF CONTENTS Page ABSTRACT .....................................................................................................................................1 CHAPTER I INTRODUCTION ...............................................................................................................3 II MATERIALS AND METHODS .........................................................................................7 Yeast strains, plasmids, and culture conditions .......................................................7 Yeast growth measurements ..................................................................................10 Yeast oxygen consumption and mitochondrial isolation .......................................11 SDS-PAGE and Western blotting ..........................................................................11 Sporulation, tetrad dissection, and genotyping ......................................................12 High-throughput phenotypic analysis of yeast strains ...........................................15 III RESULTS ..........................................................................................................................16
    [Show full text]
  • Inborn Errors of Metabolism Test Requisition
    LABORATORY OF GENETICS AND GENOMICS Mailing Address: For local courier service and/or inquiries, please contact 513-636-4474 • Fax: 513-636-4373 3333 Burnet Avenue, Room R1042 www.cincinnatichildrens.org/moleculargenetics • Email: [email protected] Cincinnati, OH 45229 INBORN ERRORS OF METABOLISM TEST REQUISITION All Information Must Be Completed Before Sample Can Be Processed PATIENT INFORMATION ETHNIC/RACIAL BACKGROUND (Choose All) Patient Name: ___________________ , ___________________ , ________ European American (White) African-American (Black) Last First MI Native American or Alaskan Asian-American Address: ____________________________________________________ Pacific Islander Ashkenazi Jewish ancestry ____________________________________________________ Latino-Hispanic _____________________________________________ Home Phone: ________________________________________________ (specify country/region of origin) MR# __________________ Date of Birth ________ / ________ / _______ Other ____________________________________________________ (specify country/region of origin) Gender: Male Female BILLING INFORMATION (Choose ONE method of payment) o REFERRING INSTITUTION o COMMERCIAL INSURANCE* Insurance can only be billed if requested at the time of service. Institution: ____________________________________________________ Policy Holder Name: _____________________________________________ Address: _____________________________________________________ Gender: ________________ Date of Birth ________ / ________ / _______
    [Show full text]
  • ACADS Rabbit Pab
    Leader in Biomolecular Solutions for Life Science ACADS Rabbit pAb Catalog No.: A0945 2 Publications Basic Information Background Catalog No. This gene encodes a tetrameric mitochondrial flavoprotein, which is a member of the A0945 acyl-CoA dehydrogenase family. This enzyme catalyzes the initial step of the mitochondrial fatty acid beta-oxidation pathway. Mutations in this gene have been Observed MW associated with short-chain acyl-CoA dehydrogenase (SCAD) deficiency. Alternative 44kDa splicing results in two variants which encode different isoforms. Calculated MW 44kDa Category Primary antibody Applications WB, IHC, IF Cross-Reactivity Human, Mouse, Rat Recommended Dilutions Immunogen Information WB 1:500 - 1:2000 Gene ID Swiss Prot 35 P16219 IHC 1:50 - 1:100 Immunogen 1:50 - 1:200 IF Recombinant fusion protein containing a sequence corresponding to amino acids 1-260 of human ACADS (NP_000008.1). Synonyms ACADS;ACAD3;SCAD Contact Product Information www.abclonal.com Source Isotype Purification Rabbit IgG Affinity purification Storage Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide,50% glycerol,pH7.3. Validation Data Western blot analysis of extracts of various cell lines, using ACADS antibody (A0945) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit (RM00020). Exposure time: 15s. Immunohistochemistry of paraffin- Immunohistochemistry of paraffin- Immunofluorescence analysis of U2OS embedded human liver cancer using embedded human liver damage using cells using ACADS antibody (A0945). Blue: ACADS antibody (A0945) at dilution of ACADS antibody (A0945) at dilution of DAPI for nuclear staining.
    [Show full text]
  • Health Effects Support Document for Perfluorooctanoic Acid (PFOA)
    United States Office of Water EPA 822-R-16-003 Environmental Protection Mail Code 4304T May 2016 Agency Health Effects Support Document for Perfluorooctanoic Acid (PFOA) Perfluorooctanoic Acid – May 2016 i Health Effects Support Document for Perfluorooctanoic Acid (PFOA) U.S. Environmental Protection Agency Office of Water (4304T) Health and Ecological Criteria Division Washington, DC 20460 EPA Document Number: 822-R-16-003 May 2016 Perfluorooctanoic Acid – May 2016 ii BACKGROUND The Safe Drinking Water Act (SDWA), as amended in 1996, requires the Administrator of the U.S. Environmental Protection Agency (EPA) to periodically publish a list of unregulated chemical contaminants known or anticipated to occur in public water systems and that may require regulation under SDWA. The SDWA also requires the Agency to make regulatory determinations on at least five contaminants on the Contaminant Candidate List (CCL) every 5 years. For each contaminant on the CCL, before EPA makes a regulatory determination, the Agency needs to obtain sufficient data to conduct analyses on the extent to which the contaminant occurs and the risk it poses to populations via drinking water. Ultimately, this information will assist the Agency in determining the most appropriate course of action in relation to the contaminant (e.g., developing a regulation to control it in drinking water, developing guidance, or deciding not to regulate it). The PFOA health assessment was initiated by the Office of Water, Office of Science and Technology in 2009. The draft Health Effects Support Document for Perfluoroctanoic Acid (PFOA) was completed in 2013 and released for public comment in February 2014.
    [Show full text]
  • FOXRED1 (D-4): Sc-377010
    SANTA CRUZ BIOTECHNOLOGY, INC. FOXRED1 (D-4): sc-377010 BACKGROUND APPLICATIONS FOXRED1 (FAD-dependent oxidoreductase domain-containing protein 1), also FOXRED1 (D-4) is recommended for detection of FOXRED1 of human origin known as FP634, is a 486 amino acid single-pass membrane protein. Utilizing by Western Blotting (starting dilution 1:100, dilution range 1:100-1:1000), FAD as a cofactor, FOXRED1 may act as a chaperone protein essential for the immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell function of mitochondrial complex I. Mutations to FOXRED1 may result in lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50- mitochondrial complex I deficiency (MT-C1D), which results in a wide range 1:500), immunohistochemistry (including paraffin-embedded sections) of clinical maladies from lethal neonatal disease to adult onset neurodegen- (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA erative disorders. Common phenotypes of MT-C1D include cardiomyopathy, (starting dilution 1:30, dilution range 1:30-1:3000). liver disease, Leigh syndrome, Leber hereditary optic neuropathy, and some Suitable for use as control antibody for FOXRED1 siRNA (h): sc-96988, forms of Parkinson disease. FOXRED1 exists as three alternatively spliced FOXRED1 shRNA Plasmid (h): sc-96988-SH and FOXRED1 shRNA (h) isoforms and is encoded by a gene mapping to human chromosome 11q24.2. Lentiviral Particles: sc-96988-V. With approximately 135 million base pairs and 1,400 genes, chromosome 11 makes up around 4% of human genomic DNA and is considered a gene and Molecular Weight of FOXRED1 isoform 1: 54 kDa.
    [Show full text]
  • Mitochondrial Protein Quality Control Mechanisms
    G C A T T A C G G C A T genes Review Mitochondrial Protein Quality Control Mechanisms Pooja Jadiya * and Dhanendra Tomar * Center for Translational Medicine, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA * Correspondence: [email protected] (P.J.); [email protected] (D.T.); Tel.: +1-215-707-9144 (D.T.) Received: 29 April 2020; Accepted: 15 May 2020; Published: 18 May 2020 Abstract: Mitochondria serve as a hub for many cellular processes, including bioenergetics, metabolism, cellular signaling, redox balance, calcium homeostasis, and cell death. The mitochondrial proteome includes over a thousand proteins, encoded by both the mitochondrial and nuclear genomes. The majority (~99%) of proteins are nuclear encoded that are synthesized in the cytosol and subsequently imported into the mitochondria. Within the mitochondria, polypeptides fold and assemble into their native functional form. Mitochondria health and integrity depend on correct protein import, folding, and regulated turnover termed as mitochondrial protein quality control (MPQC). Failure to maintain these processes can cause mitochondrial dysfunction that leads to various pathophysiological outcomes and the commencement of diseases. Here, we summarize the current knowledge about the role of different MPQC regulatory systems such as mitochondrial chaperones, proteases, the ubiquitin-proteasome system, mitochondrial unfolded protein response, mitophagy, and mitochondria-derived vesicles in the maintenance of mitochondrial proteome and health. The proper understanding of mitochondrial protein quality control mechanisms will provide relevant insights to treat multiple human diseases. Keywords: mitochondria; proteome; ubiquitin; proteasome; chaperones; protease; mitophagy; mitochondrial protein quality control; mitochondria-associated degradation; mitochondrial unfolded protein response 1. Introduction Mitochondria are double membrane, dynamic, and semiautonomous organelles which have several critical cellular functions.
    [Show full text]